CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 261 enrolled
Drug / intervention
Adalimumab +2 moredrug
Likely dose
Adalimumab 80 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01124838
NCT01124838Phase 3Completed
CompareCT.gov

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients

AbbVie (prior sponsor, Abbott)·interventional·Posted May 17, 2010·Updated Jul 7, 2021

In Brief

A Phase 3 clinical trial evaluating Adalimumab, Prednisone, and 1 other intervention for Uveitis. Completed, enrolled 261 participants.

Detailed Summary

A study comparing the safety and efficacy of adalimumab compared with. placebo in adults with inactive non-infectious intermediate uveitis, posterior uveitis, or panuveitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 17, 2010
Enrollment StartAug 1, 2010
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 16.1 years ago

Interventions

Adalimumabdrug

Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.

Prednisonedrug

Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.

Placebodrug

Administered by subcutaneous injection